(MD) Mednax - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58502B1061

Stock: Neonatal Care, Maternal-Fetal Care, Pediatric Subspecialty Services

Total Rating 55

Risk 82

Buy Signal -1.24

Medical Care Facilities » Health Care Services
Age: 30.4y

Market Cap: 1,862m
Avg Trading Vol: 11.7M USD

ATR: 3.47%
Peers RS (IBD): 75.68

EPS (Earnings per Share)

EPS CAGR: -45.94%
EPS Trend: -5.8%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -0.30%
Rev. Trend: -21.3%

Last SUE: 1.25
Qual. Beats: 1

Risk 5d forecast
Volatility	45.0%
Relative Tail Risk	-13.5%

Reward TTM
Sharpe Ratio	0.99
Alpha	36.54

Character TTM
Beta	0.761
Beta Downside	0.929

Drawdowns 3y
Max DD	59.49%
CAGR/Max DD	0.20

Description: MD Mednax January 19, 2026

Pediatrix Medical Group, Inc. (formerly MEDNAX) delivers hospital-based newborn, maternal-fetal, and pediatric subspecialty services across the United States. Its clinical model relies on physician-led teams-including neonatal intensivists, maternal-fetal medicine specialists, and pediatric surgeons-who staff NICUs, labor & delivery suites, pediatric emergency departments, and related support units.

Key industry metrics that shape Pediatrix’s outlook include the U.S. NICU occupancy rate (≈ 71% in 2023, a modest rise from pre-pandemic levels) and the growth of high-risk pregnancies, which has been driven by rising maternal age and obesity prevalence-both factors that historically boost demand for maternal-fetal and neonatal care. On the financial side, the company reported FY 2023 revenue of $2.4 billion with a 4.2% operating margin, while the broader health-care services sector is benefitting from a 2.5% CAGR in outpatient pediatric services driven by shifting payer policies toward value-based reimbursement.

For a deeper, data-driven view of how these trends may affect MD’s valuation, you might explore the analytics platform ValueRay for granular, real-time financial modeling.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income: 162.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.12 > 0.02 and ΔFCF/TA 6.88 > 1.0
NWC/Revenue: 16.89% < 20% (prev 7.73%; Δ 9.16% < -1%)
CFO/TA 0.13 > 3% & CFO 290.0m > Net Income 162.2m
Net Debt (302.2m) to EBITDA (258.3m): 1.17 < 3
Current Ratio: 1.83 > 1.5 & < 3
Outstanding Shares: last quarter (85.6m) vs 12m ago 1.29% < -2%
Gross Margin: 25.81% > 18% (prev 0.21%; Δ 2560 % > 0.5%)
Asset Turnover: 89.91% > 50% (prev 96.64%; Δ -6.72% > 0%)
Interest Coverage Ratio: 7.57 > 6 (EBITDA TTM 258.3m / Interest Expense TTM 31.1m)

Altman Z'' 1.44

A: 0.15 (Total Current Assets 717.2m - Total Current Liabilities 392.5m) / Total Assets 2.20b
B: -0.05 (Retained Earnings -116.8m / Total Assets 2.20b)
C: 0.11 (EBIT TTM 235.2m / Avg Total Assets 2.14b)
D: -0.09 (Book Value of Equity -115.5m / Total Liabilities 1.31b)
Altman-Z'' Score: 1.44 = BB

Beneish M -3.46

DSRI: 0.84 (Receivables 231.1m/288.1m, Revenue 1.92b/2.01b)
GMI: 0.82 (GM 25.81% / 21.27%)
AQI: 0.92 (AQ_t 0.64 / AQ_t-1 0.70)
SGI: 0.96 (Revenue 1.92b / 2.01b)
TATA: -0.06 (NI 162.2m - CFO 290.0m) / TA 2.20b)
Beneish M-Score: -3.46 (Cap -4..+1) = AA

What is the price of MD shares?

As of February 07, 2026, the stock is trading at USD 20.89 with a total of 550,654 shares traded.
Over the past week, the price has changed by -2.29%, over one month by -6.28%, over three months by -4.26% and over the past year by +52.48%.

Is MD a buy, sell or hold?

Mednax has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MD.

StrongBuy: 3
Buy: 0
Hold: 5
Sell: 0
StrongSell: 0

What are the forecasts/targets for the MD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.7	8.5%
Analysts Target Price	22.7	8.5%
ValueRay Target Price	21.4	2.2%

MD Fundamental Data Overview February 03, 2026

P/E Trailing = 10.9641
P/E Forward = 8.7873
P/S = 0.9685
P/B = 2.0248
P/EG = 0.88
Revenue TTM = 1.92b USD
EBIT TTM = 235.2m USD
EBITDA TTM = 258.3m USD
Long Term Debt = 577.2m USD (from longTermDebt, last quarter)
Short Term Debt = 37.6m USD (from shortTermDebt, last quarter)
Debt = 642.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 302.2m USD (from netDebt column, last quarter)
Enterprise Value = 2.16b USD (1.86b + Debt 642.3m - CCE 340.1m)
Interest Coverage Ratio = 7.57 (Ebit TTM 235.2m / Interest Expense TTM 31.1m)
EV/FCF = 7.92x (Enterprise Value 2.16b / FCF TTM 273.4m)
FCF Yield = 12.63% (FCF TTM 273.4m / Enterprise Value 2.16b)
FCF Margin = 14.22% (FCF TTM 273.4m / Revenue TTM 1.92b)
Net Margin = 8.44% (Net Income TTM 162.2m / Revenue TTM 1.92b)
Gross Margin = 25.81% ((Revenue TTM 1.92b - Cost of Revenue TTM 1.43b) / Revenue TTM)
Gross Margin QoQ = 28.48% (prev 26.60%)
Tobins Q-Ratio = 0.98 (Enterprise Value 2.16b / Total Assets 2.20b)
Interest Expense / Debt = 0.48% (Interest Expense 3.06m / Debt 642.3m)
Taxrate = 18.31% (16.1m / 87.8m)
NOPAT = 192.2m (EBIT 235.2m * (1 - 18.31%))
Current Ratio = 1.83 (Total Current Assets 717.2m / Total Current Liabilities 392.5m)
Debt / Equity = 0.72 (Debt 642.3m / totalStockholderEquity, last quarter 890.7m)
Debt / EBITDA = 1.17 (Net Debt 302.2m / EBITDA 258.3m)
Debt / FCF = 1.11 (Net Debt 302.2m / FCF TTM 273.4m)
Total Stockholder Equity = 819.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.59% (Net Income 162.2m / Total Assets 2.20b)
RoE = 19.79% (Net Income TTM 162.2m / Total Stockholder Equity 819.6m)
RoCE = 16.84% (EBIT 235.2m / Capital Employed (Equity 819.6m + L.T.Debt 577.2m))
RoIC = 13.45% (NOPAT 192.2m / Invested Capital 1.43b)
WACC = 6.58% (E(1.86b)/V(2.50b) * Re(8.72%) + D(642.3m)/V(2.50b) * Rd(0.48%) * (1-Tc(0.18)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.94%
[DCF Debug] Terminal Value 86.02% ; FCFF base≈210.1m ; Y1≈259.2m ; Y5≈441.4m
Fair Price DCF = 117.8 (EV 10.42b - Net Debt 302.2m = Equity 10.12b / Shares 85.9m; r=6.58% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -5.82 | EPS CAGR: -45.94% | SUE: -4.0 | # QB: 0
Revenue Correlation: -21.31 | Revenue CAGR: -0.30% | SUE: 1.25 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.38 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=5
EPS next Year (2026-12-31): EPS=2.19 | Chg30d=+0.000 | Revisions Net=+6 | Growth EPS=+4.9% | Growth Revenue=+2.7%

Additional Sources for MD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle